trending Market Intelligence /marketintelligence/en/news-insights/trending/Zjalx8yICwHFtS4VHDB3mQ2 content esgSubNav
In This List

KemPharm's acute pain drug gains FDA fast-track designation

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


KemPharm's acute pain drug gains FDA fast-track designation

The U.S. FDA granted fast-track designation to KemPharm Inc.'s co-lead product candidate, KP201/IR, for the treatment of acute pain.

The company plans to start human clinical trials of the product in the first half of 2017.

KemPharm remains on target for the potential submission of a new drug application for KP201/IR in 2018, President and CEO Travis Mickle said in a statement.